Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | CA12 | O43570 | 1/20 | 0.53 |
| ▸ | CA1 | P00915 | 1/20 | 0.53 |
| ▸ | CA2 | P00918 | 1/20 | 0.53 |
| ▸ | CA9 | Q16790 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.53 |
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23929061 | 0.84 | SMN1; SMN2 (0.82) | KMT2ASMN1; SMN2POLBTDP1CA12 | |
| SCHEMBL3464761 | 0.84 | SMN1; SMN2 (0.59) | KMT2ASMN1; SMN2POLBTDP1CA12 | |
| SCHEMBL5176558 | 0.84 | SMN1; SMN2 (0.59) | KMT2ASMN1; SMN2POLBTDP1CA12 | |
| SCHEMBL3464764 | 0.84 | SMN1; SMN2 (0.59) | KMT2ASMN1; SMN2POLBTDP1CA12 | |
| SCHEMBL10013657 | 0.83 | CA12 (0.55) | KMT2ASMN1; SMN2POLBCA12CA1 | |
| SCHEMBL18628077 | 0.82 | SMN1; SMN2 (0.58) | KMT2ASMN1; SMN2POLBTDP1CA12 | |
| SCHEMBL992153 | 0.82 | SMN1; SMN2 (0.58) | KMT2ASMN1; SMN2POLBTDP1CA12 | |
| Hydrochloric Acid SCHEMBL5047728 | 0.82 | SMN1; SMN2 (0.58) | KMT2ASMN1; SMN2POLBTDP1CA12 | |
| SCHEMBL24391511 | 0.82 | SMN1; SMN2 (0.58) | KMT2ASMN1; SMN2POLBTDP1CA12 | |
| SCHEMBL2697889 | 0.82 | SMN1; SMN2 (0.58) | KMT2ASMN1; SMN2POLBTDP1CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112074523-B | Compounds as protease activated receptor 4(PAR4) inhibitors for the treatment of platelet aggregation | 深圳信立泰药业股份有限公司 | 2022-08-09 | — | — | CN | disclosed |
| CN-112074523-A | Compounds as protease activated receptor 4(PAR4) inhibitors for the treatment of platelet aggregation | 深圳信立泰药业股份有限公司 | 2020-12-11 | — | — | CN | disclosed |
| US-9709557-B2 | Anthraquinone based near IR emitting compounds and uses thereof | Life Technologies Corporation (US) | 2017-07-18 | — | — | US | disclosed |
| US-9709557-B2 | Anthraquinone based near IR emitting compounds and uses thereof | Life Technologies Corporation (US) | 2017-07-18 | — | — | US | disclosed |
| US-20150168383-A1 | ANTHRAQUINONE BASED NEAR IR EMITTING COMPOUNDS AND USES THEREOF | Life Technologies Corporation | 2015-06-18 | — | — | US | disclosed |
| US-20150168383-A1 | ANTHRAQUINONE BASED NEAR IR EMITTING COMPOUNDS AND USES THEREOF | Life Technologies Corporation | 2015-06-18 | — | — | US | disclosed |
| US-8999965-B2 | Anthraquinone based near IR emitting compounds and uses thereof | Life Technologies Corporation (US) | 2015-04-07 | — | — | US | disclosed |
| US-8999965-B2 | Anthraquinone based near IR emitting compounds and uses thereof | Life Technologies Corporation (US) | 2015-04-07 | — | — | US | disclosed |
| EP-1888082-B1 | MOTILIDE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2012-09-12 | — | — | EP | disclosed |
| US-20120028249-A1 | ANTHRAQUINONE BASED NEAR IR EMITTING COMPOUNDS AND USES THEREOF | Life Technologies Corporation (US) | 2012-02-02 | — | — | US | disclosed |
| US-20120028249-A1 | ANTHRAQUINONE BASED NEAR IR EMITTING COMPOUNDS AND USES THEREOF | Life Technologies Corporation (US) | 2012-02-02 | — | — | US | disclosed |
| US-7582611-B2 | Treating disorders of gastric motility; decreasing side effects of erythromycin A | PFIZER INC. (US) | 2009-09-01 | — | — | US | disclosed |
| EP-1888082-A4 | MOTILIDE COMPOUNDS | PFIZER (US) | 2008-12-17 | — | — | EP | disclosed |
| EP-1888082-A1 | MOTILIDE COMPOUNDS | Pfizer, Inc. (US) | 2008-02-20 | — | — | EP | disclosed |
| WO-2006127252-A1 | MOTILIDE COMPOUNDS | PFIZER, INC. (US) | 2006-11-30 | — | — | WO | disclosed |
| US-20060270616-A1 | Motilide compounds | PFIZER INC. | 2006-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028249-A1 | ANTHRAQUINONE BASED NEAR IR EMITTING COMPOUNDS AND USES THEREOF | ANTXR2, AAAS, IK | KMT2A 4543/4885SMN1; SMN2 4791/4885POLB 1704/4885 |
| US-20060270616-A1 | Motilide compounds | MLNR, PROKR1, GIPR | KMT2A 4195/4885SMN1; SMN2 240/4885POLB 1908/4885 |
| US-20150168383-A1 | ANTHRAQUINONE BASED NEAR IR EMITTING COMPOUNDS AND USES THEREOF | ANTXR2, AAAS, IK | KMT2A 4543/4885SMN1; SMN2 4791/4885POLB 1704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.